RT Journal Article
T1 Personalized Cancer Nanomedicine: Overcoming BiologicalBarriers for Intracellular Delivery of Biopharmaceuticals
A1 López Estévez, Ana María
A1 Lapuhs, Philipp
A1 Piñeiro Alonso, Laura
A1 Alonso Fernández, María José
K1 Cancer
K1 Intracellular
K1 Monoclonal antibody
K1 Nanotechnology
K1 RNA
AB The success of personalized medicine in oncology relies on using highlyeffective and precisetherapeutic modalities such as small interfering RNA(siRNA) and monoclonal antibodies (mAbs). Unfortunately, the clinicalexploitation of these biological drugs has encountered obstacles inovercoming intricate biological barriers. Drug delivery technologies representa plausible strategy to overcome such barriers, ultimately facilitating theaccess to intracellular domains. Here, an overview of the current landscapeon how nanotechnology has dealt with protein corona phenomena as a firstand determinant biological barrier is presented. This continues with theanalysis of strategies facilitating access to the tumor, along with conceivablemethods for enhanced tumor penetration. As a final step, the cellular barriersthat nanocarriers must confront in order for their biological cargo to reachtheir target are deeply analyzed. This review concludes with a critical analysisand future perspectives of the translational advances in personalizedoncological nanomedicine
PB Wiley
SN 0935-9648
YR 2023
FD 2023
LK http://hdl.handle.net/10347/32892
UL http://hdl.handle.net/10347/32892
LA eng
NO A. M. López-Estévez, P. Lapuhs, L. Pineiro-Alonso, M. J. Alonso, Personalized Cancer Nanomedicine: Overcoming Biological Barriers for Intracellular Delivery of Biopharmaceuticals. Adv. Mater. 2023, 2309355. https://doi.org/10.1002/adma.202309355
DS Minerva
RD 28 abr 2026